J. Llorin-Sangalang

Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.

A. Zelenetz, A. Iasonos, A. Stathis, 2022, The Lancet. Oncology.

A PIVOTAL, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, TWO‐ARM, PHASE 2 STUDY OF ME‐401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES

A. Zelenetz, P. Abrisqueta, C. Buske, 2019, Hematological Oncology.

THE PI3Kδ INHIBITOR ME‐401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)

A. Iasonos, A. Stathis, J. Pagel, 2019, Hematological Oncology.

Tolerability and durable respones of the PI3Kδ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies.

A. Zelenetz, A. Stathis, J. Pagel, 2020 .

Abstract OT3-06-01: SHERBOC: A double-blind, placebo-controlled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy

Hong Zhang, T. Bloom, G. Finn, 2018 .